GENEVA—Evidence presented at the 2015 European Lung Cancer conference from the large SQUIRE multicenter open label study points to the fact that older patients with squamous non small cell lung cancer can benefit from a three drug regimen including the EGFR-targeted agent necitumumab. Nicholas Thatcher, MD PhD—who is Professor of Oncology at the University of Manchester—explained to Oncology Times reporter Peter Goodwin how the outcome data from SQUIRE give reassurance that older patients can benefit from such new combinations—without the need to resort to more gentle regimens—provided attention is paid to the influence of co-morbidities.
You may also like...
- Previous story Controlling Side Effects from Targeted Drugs in Lung Cancer
- Next story Immunotherapy: Standard of Care in Waiting for Non Small-Cell Lung Cancer
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014
- MMR vaccine’s non-specific effects: adherence to recommended vaccination schedules protects children against non-vaccination-specific infections tooFebruary 28, 2014